QPS Strengthens Elemental Bioanalysis Capabilities with Acquisition of Two NexION 2200 ICP-MS Systems QPS Holdings, LLC (QPS), a global contract research organization supporting pharmaceutical and drug development programs, has announced a major investment in its elemental bioanalysis infrastructure with the…
Perfuze Reports Strong Final MARRS Pivotal Study Results Supporting Millipede88 Aspiration System in Acute Ischemic Stroke Perfuze, a medical device company focused on advancing stroke intervention through next-generation catheter technology, has announced the publication of final results from its MARRS…
TRex Bio Reports Positive Phase 1a Results for TRB-061, Supporting Treg Activation in Atopic Dermatitis TRex Bio, Inc. (TRexBio), a clinical-stage biotechnology company focused on tissue regulatory T-cell (Treg) biology and the discovery and development of immunoregulatory medicines, has announced…
McKesson to Acquire Precision Medicine Group for Approximately $2.25 Billion to Expand Oncology and Biopharma Services McKesson Corporation (NYSE: MCK) has announced a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharmaceutical commercialization…
Pretzel Therapeutics Receives FDA Clearance to Advance PX578 Into Phase 2 Study for POLG-Mediated Mitochondrial Disease Pretzel Therapeutics, Inc., a clinical-stage biotechnology company focused on developing a new generation of medicines designed to restore mitochondrial function, improve cellular energy production…
Precision BioSciences Doses First Patient in Phase 1/2 FUNCTION-DMD Trial of PBGENE-DMD for Duchenne Muscular Dystrophy Precision BioSciences, Inc., a clinical-stage gene editing company developing in vivo therapies for diseases with significant unmet medical needs, has announced that the first…
Charles River Laboratories and Medigen Vaccine Biologics Collaborate to Advance Next-Generation Multivalent Enterovirus Vaccine Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) have entered into a strategic collaboration focused on the characterization and validation of the virus seed bank…
Mitochon Pharmaceuticals Receives $1 Million ALS Association Award to Advance MP-101 Clinical Development Mitochon Pharmaceuticals has announced that it has received a $1 million Hoffman ALS Clinical Trial Award from The ALS Association to support the continued clinical development of…
NTx Bio Platform Supports Personalized mRNA Vaccine Manufacturing for Phase 1 Melanoma Trial NTx Bio, a company developing next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used by researchers at Baylor College of Medicine to manufacture messenger…
Merck and Moderna Report Positive Phase 3 Results for Personalized mRNA Cancer Therapy in Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc. have announced positive topline results from the Phase 3 INTerpath-001 clinical trial…
BeOne Medicines, BeOne Care Foundation and The Max Foundation Renew Partnership to Expand BRUKINSA Access for Patients With CLL BeOne Medicines Ltd., a global oncology company, has announced the renewal of its partnership with the BeOne Care Foundation and The…
Cardio Diagnostics Launches In-House CLIA-Certified Laboratory to Advance Precision Cardiovascular Testing Cardio Diagnostics Holdings, Inc., an artificial intelligence-driven precision cardiovascular medicine company, has announced the official launch of its new high-complexity, Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in Iowa City,…